Novartis's dual-acting antihypertensive shows promise in Phase II
This article was originally published in Scrip
Executive Summary
Novartis's novel LCZ696, an angiotensin receptor blocker (ARB) and neprilysin inhibitor, improved blood pressure significantly in patients with mild-to-moderate hypertension. The Phase II study presented last week in a poster session at the American College of Cardiology (ACC) meeting in Atlanta and simultaneously published in The Lancet.